October 24, 2016 / 12:45 PM / 3 years ago

BRIEF-Atyr Pharma receives FDA fast track designation for Resolaris to treat FSHD

Oct 24 (Reuters) - Atyr Pharma Inc

* Atyr Pharma receives FDA fast track designation for Resolaris to treat facioscapulohumeral muscular dystrophy (FSHD)

* Atyr Pharma Inc - expects to report data from three phase 1B/2 clinical programs for Resolaris in December 2016 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below